Monograph Details
|
|
Endocrine System
> Diabetes
|
|
AMARYL |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Sulfonylurea. |
| Generic Name |
|
Glimepiride 1mg, 2mg, 4mg; scored tabs. |
| Indications |
|
Adjunct to diet and exercise in type 2 diabetes, alone or in combination with metformin. Secondary failure in combination with insulin. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 1–2mg once daily with breakfast or first main meal; after reaching a dose of 2mg increase by up to 2mg at 1–2 week intervals if needed. Usual maintenance: 1–4mg once daily; max 8mg/day. Prior sensitivity to hypoglycemic agents or impaired renal function: initially 1mg once daily, titrate carefully. Secondary failure: initiate combination therapy for fasting blood glucose levels >150mg/dL. Use 8mg glimepiride once daily with first main meal and titrate with low-dose insulin as needed. |
| Contraindications |
|
Ketoacidosis. |
| Precautions |
|
Impaired renal or hepatic function. Adrenal or pituitary insufficiency. Stress. Secondary failure may occur with extended therapy. Discontinue if skin reactions persist. Elderly. Debilitated. Malnourished. Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended. |
| Interactions |
|
May be potentiated by alcohol, NSAIDs, highly protein bound drugs, miconazole, salicylates, sulfonamides, warfarin, chloramphenicol, probenecid, MAOIs, β-blockers. May be antagonized by diuretics, corticosteroids, phenothiazines, thyroid products, phenytoin, niacin, sympathomimetics, isoniazid, estrogens, oral contraceptives. Disulfiram reactions have been reported with other sulfonylureas. Monitor for 1–2 weeks if transferring from long-acting sulfonylureas. Monitor for hypoglycemia if used with insulin or metformin. |
| Adverse Reactions |
|
Increased risk of cardiovascular mortality. Hypoglycemia, dizziness, asthenia, headache, nausea, allergic skin reactions, blood dyscrasias. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
